Role of platelet-activating factor in skeletal muscle ischemia- reperfusion injury

7Citations
Citations of this article
4Readers
Mendeley users who have this article in their library.
Get full text

Abstract

These studies indicate that PAF, a known stimulator of aggregation, secretory and/or contractile activity of platelets, neutrophils, smooth muscle and other cells, is produced by skeletal muscle during IRI. The maximum increase occurs at 10 to 15 minutes and continues for at least an hour. Infusions of PAF into skeletal muscle subjected to 20 minutes of ischemia and 20 hours of reperfusion resulted in tissue necrosis similar to that produced by 5 hours of ischemia and 20 hours of reperfusion. 25mg/kg of pentoxifylline, infused immediately prior to reperfusion of ischemic skeletal muscle, decreased PAF production and muscle necrosis. It was also demonstrated that skeletal muscle necrosis can be reduced by infusion of PAF antagonists (WEB-2086) into the muscle immediately prior to reperfusion. Thus, PAF has an important role in skeletal muscle IRI and additional studies of PAF inhibition during IRI are warranted.

Cite

CITATION STYLE

APA

Silver, D., Dhar, A., Slocum, M., Adams, J. G., & Shukla, S. (1997). Role of platelet-activating factor in skeletal muscle ischemia- reperfusion injury. Advances in Experimental Medicine and Biology, 416, 217–221. https://doi.org/10.1007/978-1-4899-0179-8_35

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free